Burning Rock Biotech (BNR) Receivables: 2020-2025
Historic Receivables for Burning Rock Biotech (BNR) over the last 6 years, with Sep 2025 value amounting to $25.8 million.
- Burning Rock Biotech's Receivables rose 8.85% to $25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.8 million, marking a year-over-year increase of 8.85%. This contributed to the annual value of $29.0 million for FY2024, which is 9.55% up from last year.
- Latest data reveals that Burning Rock Biotech reported Receivables of $25.8 million as of Q3 2025, which was down 2.62% from $26.5 million recorded in Q2 2025.
- In the past 5 years, Burning Rock Biotech's Receivables registered a high of $29.0 million during Q4 2024, and its lowest value of $14.4 million during Q3 2022.
- In the last 3 years, Burning Rock Biotech's Receivables had a median value of $22.0 million in 2025 and averaged $22.8 million.
- Its Receivables has fluctuated over the past 5 years, first decreased by 28.73% in 2022, then surged by 34.42% in 2023.
- Burning Rock Biotech's Receivables (MRQ) stood at $27.3 million in 2021, then rose by 3.49% to $28.2 million in 2022, then decreased by 6.16% to $26.5 million in 2023, then rose by 9.55% to $29.0 million in 2024, then decreased by 10.98% to $25.8 million in 2025.
- Its Receivables stands at $25.8 million for Q3 2025, versus $26.5 million for Q2 2025 and $22.0 million for Q1 2025.